Why Hikma has cut sales forecasts for the second time this year
Pharma company Hikma (HIK) continues to have a difficult year after slashing sales forecasts for both its injectables and generics divisions and downgrading full year revenue expectations to $2bn.This is the second revenue downgrade...
17 August 2017
